Ambrx Biopharma Stock Rating Reaffirmed by Robert W. Baird
AMAMDelisted Stock | USD 15.73 0.71 4.73% |
About 55% of Ambrx Biopharma's investors are presently thinking to get in. The analysis of current outlook of investing in Ambrx Biopharma American suggests that some traders are interested regarding Ambrx Biopharma's prospects. Ambrx Biopharma's investing sentiment overview a quick insight into current market opportunities from investing in Ambrx Biopharma American. Many technical investors use Ambrx Biopharma American stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Ambrx |
Robert W. Baird reiterated their neutral rating on shares of Ambrx Biopharma in a report released on Tuesday, Benzinga reports. The brokerage currently has a 28.00 price objective on the stock. A number of other research analysts have also recently weighed in on AMAM. The Goldman Sachs Group lowered their price
Read at thelincolnianonline.com
Ambrx Biopharma Fundamental Analysis
We analyze Ambrx Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ambrx Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ambrx Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Ambrx Biopharma is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Ambrx Biopharma American Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ambrx Biopharma stock to make a market-neutral strategy. Peer analysis of Ambrx Biopharma could also be used in its relative valuation, which is a method of valuing Ambrx Biopharma by comparing valuation metrics with similar companies.
Peers
Ambrx Biopharma Related Equities
ZURA | Zura Bio | 6.82 | ||||
XFOR | X4 Pharmaceuticals | 6.06 | ||||
OCEA | Ocean Biomedical | 5.26 | ||||
ELEV | Elevation Oncology | 2.99 | ||||
INZY | Inozyme Pharma | 1.37 | ||||
IMMX | Immix Biopharma | 1.52 | ||||
DAWN | Day One | 3.81 | ||||
ABOS | Acumen Pharmaceuticals | 3.85 | ||||
SONN | Sonnet Biotherapeutics | 4.62 | ||||
HEPA | Hepion Pharmaceuticals | 5.26 | ||||
ENVB | Enveric Biosciences | 46.41 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Consideration for investing in Ambrx Stock
If you are still planning to invest in Ambrx Biopharma American check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ambrx Biopharma's history and understand the potential risks before investing.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data |